| MEDI | Wednesday, 16 March 2005 | ||
1:30 PM-4:35 PM Convention Center -- Room 6C, Oral | |||
Drug Resistant Tuberculosis | |||
| Organizer: | I Ojima | ||
| 1:30 PM | Introductory Remarks | ||
| 1:35 PM | 311 | Development of new tuberculosis drug candidates Barbara E. Laughon | |
| 2:05 PM | 312 | Development of nitrofuranylamides as antituberculosis agents Richard E Lee, Rajendra P Tangallapally, Raghunandan Yendapally, Robin E.B. Lee, AnTawan J. Daniels, Kirk Hevener | |
| 2:35 PM | 313 | Screening novel anti-tuberculosis agents effective against MDR-TB Makoto Matsumoto | |
| 3:05 PM | 314 | Why does multidrug chemotherapy still allow the emergence of drug resistance during tuberculosis treatment? Clifton E. Barry III | |
| 3:35 PM | 315 | Novel inhibitors of InhA, the enoyl reductase from Mycobacterium tuberculosis Peter J. Tonge, Todd J. Sullivan, Polina Novichenok, James J. Truglio, Caroline Kisker, Francis Johnson, Richard A. Slayden | |
| 4:05 PM | 316 | Cell wall of Mycobacterium tuberculosis and drug discovery Patrick J. Brennan | |
Symposium Grid -- Division of Medicinal Chemistry -- Session Listing
The 229th ACS National Meeting, in San Diego, CA, March 13-17, 2005